Literature DB >> 10492403

Expression and molecular cloning of human liver leukotriene B4 omega-hydroxylase (CYP4F2) gene.

Y Kikuta1, Y Miyauchi, E Kusunose, M Kusunose.   

Abstract

Human liver leukotriene B4 (LTB4) omega-hydroxylase (CYP4F2) plays an important role in the metabolic inactivation and degradation of LTB4, a potent mediator of inflammation. The regulatory mechanism for the transcription of CYP4F2 has not yet been clarified. Here, we report that CYP4F2 is constitutively expressed in a human hepatoma cell line, HepG2, and is not induced by clofibrate. We isolated the gene encoding CYP4F2 and determined its genomic organization and the functional activity of its promoters. The CYP4F2 gene contains at least 13 exons with its open reading frame being encoded from exon II to exon XIII. Exon I includes 49 bp of a 5' untranslated sequence. The structure of this gene is very similar to that of the CYP4F3 gene earlier reported by Kikuta et al. (DNA Cell Biol 1998;17:221-230). The 5' flanking sequence downstream from -165 of the CYP4F2 gene has 75% similarity to the corresponding region of the CYP4F3 gene. However, common putative regulating elements in the two human CYP4F genes were not detected except for the TATA box. The elements recognized by nuclear receptors were not observed within its 5' flanking region. Deletion of the 5' flanking regions containing putative regulating elements recognized by HNF-3beta, CDP CR, and p300 caused alterations in the transcriptional activity. The region from -83 to -67 was necessary for transcription, but the TATA sequence was not. Our results indicate that the human two CYP4F genes evolved by duplication and alterations of the transcription regulation region and the site of exon III.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492403     DOI: 10.1089/104454999315006

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  7 in total

Review 1.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

2.  Inhibition of oxidative metabolism of tocopherols with omega-N-heterocyclic derivatives of vitamin E.

Authors:  Stephan Ohnmacht; Phillip Nava; Ryan West; Robert Parker; Jeffrey Atkinson
Journal:  Bioorg Med Chem       Date:  2008-07-13       Impact factor: 3.641

3.  Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.

Authors:  Jie-Hui Li; Guo-Guo Ma; Shu-Qiang Zhu; Hao Yan; Yong-Bing Wu; Jian-Jun Xu
Journal:  J Cardiothorac Surg       Date:  2012-09-27       Impact factor: 1.637

4.  A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders.

Authors:  T Yokomizo; K Kato; K Terawaki; T Izumi; T Shimizu
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

Review 5.  The Physiological Roles of Vitamin E and Hypovitaminosis E in the Transition Period of High-Yielding Dairy Cows.

Authors:  Satoshi Haga; Hiroshi Ishizaki; Sanggun Roh
Journal:  Animals (Basel)       Date:  2021-04-11       Impact factor: 2.752

6.  Deciphering Genetic Susceptibility to Tuberculous Meningitis.

Authors:  Haiko Schurz; Brigitte Glanzmann; Nicholas Bowker; Ronald van Toorn; Regan Solomons; Johan Schoeman; Paul D van Helden; Craig J Kinnear; Eileen G Hoal; Marlo Möller
Journal:  Front Neurol       Date:  2022-03-25       Impact factor: 4.003

7.  Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response.

Authors:  J E Zhang; Kathrin Klein; Andrea L Jorgensen; Ben Francis; Ana Alfirevic; Stephane Bourgeois; Panagiotis Deloukas; Ulrich M Zanger; Munir Pirmohamed
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.